New biomarker may predict which cancer drugs work best

NCT ID NCT05461430

Completed Knowledge-focused Sponsor: Travera Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guide treatment decisions more quickly than current methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this biomarker could help doctors quickly choose the most effective therapy for individual cancer patients.

What could go wrong

This is a small, completed observational study. The biomarker needs much larger validation before it could be used in routine care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anal carcinoma anus neoplasm appendiceal neoplasm appendix carcinoma Ascites breast carcinoma breast neoplasm cancer of unknown primary site carcinoma carcinoma of esophagus cervical carcinoma cholangiocarcinoma colonic neoplasm Esophageal Neoplasms exocrine pancreatic carcinoma gastric neoplasm gastrointestinal stromal tumor head and neck squamous cell carcinoma hepatocellular carcinoma laryngeal carcinoma laryngeal neoplasm lung neoplasm malignant pancreatic neoplasm melanoma mesothelioma Mouth Neoplasms nasopharyngeal carcinoma nasopharyngeal neoplasm Neoplasms, Unknown Primary neuroendocrine carcinoma non-small cell lung carcinoma oral cavity carcinoma oropharyngeal carcinoma oropharynx cancer ovarian cancer ovarian carcinoma pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm penile carcinoma penile neoplasm Pleural Effusion, Malignant renal carcinoma renal cell adenocarcinoma renal cell carcinoma small cell carcinoma thymic carcinoma thymoma urinary bladder carcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms vulva cancer vulvar carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASCITES, MALIGNANT CARCINOMA CARCINOMA BLADDER CARCINOMA BREAST CARCINOMA OF ESOPHAGUS CARCINOMA OF THE ANUS CARCINOMA OF THE APPENDIX CARCINOMA OF THE BLADDER CARCINOMA OF THE CERVIX CARCINOMA OF THE HEAD AND NECK CARCINOMA OF THE LARYNX CARCINOMA OF THE NASOPHARYNX CARCINOMA OF THE ORAL CAVITY CARCINOMA OF THE OROPHARYNX CARCINOMA OF THE PENIS CARCINOMA OF THE VULVA CARCINOMA OF UNKNOWN PRIMARY CARCINOMA, HEPATOCELLULAR CARCINOMA, NEUROENDOCRINE CARCINOMA, NON-SMALL-CELL LUNG CARCINOMA, OVARIAN CARCINOMA, PANCREATIC CARCINOMA, PANCREATIC DUCTAL CARCINOMA, RENAL CARCINOMA, RENAL CELL CARCINOMA, SMALL CELL CARCINOMA, THYMIC CHOLANGIOCARCINOMA MELANOMA MESOTHELIOMA PANCREATIC CANCER PLEURAL EFFUSION, MALIGNANT

Contacts and locations

Show contact details

Locations

xCures

Oakland, California, 94612, United States